Published in Immunobiology on August 08, 2012
Modulation of inflammation by interleukin-27. J Leukoc Biol (2013) 0.95
MicroRNA-26b Modulates the NF-κB Pathway in Alveolar Macrophages by Regulating PTEN. J Immunol (2015) 0.78
Soluble CD40 Ligand in Sera of Subjects Exposed to Leishmania infantum Infection Reduces the Parasite Load in Macrophages. PLoS One (2015) 0.77
Biology of IL-27 and its role in the host immunity against Mycobacterium tuberculosis. Int J Biol Sci (2015) 0.77
Integrin αvβ3 enhances the suppressive effect of interferon-γ on hematopoietic stem cells. EMBO J (2017) 0.75
Local expression of interleukin-27 ameliorates collagen-induced arthritis. Arthritis Rheum (2011) 2.40
The IL-27 receptor chain WSX-1 differentially regulates antibacterial immunity and survival during experimental tuberculosis. J Immunol (2005) 2.26
Potent antitumor activity of interleukin-27. Cancer Res (2004) 1.80
An indispensable role for STAT1 in IL-27-induced T-bet expression but not proliferation of naive CD4+ T cells. J Immunol (2004) 1.66
Regulation of antitumor immune responses by the IL-12 family cytokines, IL-12, IL-23, and IL-27. Clin Dev Immunol (2010) 1.59
Phosphorylation of the adaptor ASC acts as a molecular switch that controls the formation of speck-like aggregates and inflammasome activity. Nat Immunol (2013) 1.51
Antiangiogenic and antitumor activities of IL-27. J Immunol (2006) 1.50
Augmentation of effector CD8+ T cell generation with enhanced granzyme B expression by IL-27. J Immunol (2005) 1.50
IL-27 suppresses Th2 cell development and Th2 cytokines production from polarized Th2 cells: a novel therapeutic way for Th2-mediated allergic inflammation. J Immunol (2007) 1.50
Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma. Cancer Res (2006) 1.49
A role for IL-27 in early regulation of Th1 differentiation. J Immunol (2005) 1.45
Notch signaling drives IL-22 secretion in CD4+ T cells by stimulating the aryl hydrocarbon receptor. Proc Natl Acad Sci U S A (2010) 1.45
IL-27 suppresses CD28-mediated [correction of medicated] IL-2 production through suppressor of cytokine signaling 3. J Immunol (2006) 1.34
Antiproliferative activity of IL-27 on melanoma. J Immunol (2008) 1.33
IL-23 enhances host defense against vaccinia virus infection via a mechanism partly involving IL-17. J Immunol (2007) 1.24
Alternatively activated macrophages express the IL-27 receptor alpha chain WSX-1. Immunobiology (2006) 1.23
Natural occurring IL-17 producing T cells regulate the initial phase of neutrophil mediated airway responses. J Immunol (2009) 1.21
Pivotal roles of T-helper 17-related cytokines, IL-17, IL-22, and IL-23, in inflammatory diseases. Clin Dev Immunol (2013) 1.20
Calpain-induced Bax-cleavage product is a more potent inducer of apoptotic cell death than wild-type Bax. Cancer Lett (2003) 1.18
IL-27 induces Th1 differentiation via p38 MAPK/T-bet- and intercellular adhesion molecule-1/LFA-1/ERK1/2-dependent pathways. J Immunol (2006) 1.15
Interferon-gamma is a therapeutic target molecule for prevention of postoperative adhesion formation. Nat Med (2008) 1.09
Epithelial cell-derived IL-25, but not Th17 cell-derived IL-17 or IL-17F, is crucial for murine asthma. J Immunol (2012) 1.08
Induction of IgG2a class switching in B cells by IL-27. J Immunol (2004) 1.07
Adjuvant activities of novel cytokines, interleukin-23 (IL-23) and IL-27, for induction of hepatitis C virus-specific cytotoxic T lymphocytes in HLA-A*0201 transgenic mice. J Virol (2004) 1.06
TGF-beta is necessary for induction of IL-23R and Th17 differentiation by IL-6 and IL-23. Biochem Biophys Res Commun (2009) 1.05
Interleukin-27 directly induces differentiation in hematopoietic stem cells. Blood (2007) 1.05
Antigen chemically coupled to the surface of liposomes are cross-presented to CD8+ T cells and induce potent antitumor immunity. J Immunol (2006) 1.02
Interleukin-27 activates natural killer cells and suppresses NK-resistant head and neck squamous cell carcinoma through inducing antibody-dependent cellular cytotoxicity. Cancer Res (2009) 1.02
STAT3 is indispensable to IL-27-mediated cell proliferation but not to IL-27-induced Th1 differentiation and suppression of proinflammatory cytokine production. J Immunol (2008) 1.01
T-bet is required for protection against vaccinia virus infection. J Virol (2005) 1.00
No inhibition of IL-27 signaling by soluble gp130. Biochem Biophys Res Commun (2005) 0.98
Dendritic cell-derived IL-12p40 homodimer contributes to susceptibility in cutaneous leishmaniasis in BALB/c mice. J Immunol (2007) 0.98
Induction of apoptosis and/or necrosis following exposure to antitumour agents in a melanoma cell line, probably through modulation of Bcl-2 family proteins. Melanoma Res (2003) 0.95
Regulation of the development of acute hepatitis by IL-23 through IL-22 and IL-17 production. Eur J Immunol (2011) 0.93
A pivotal role for interleukin-27 in CD8+ T cell functions and generation of cytotoxic T lymphocytes. J Biomed Biotechnol (2010) 0.93
Sustained upregulation of effector natural killer cells in chronic myeloid leukemia after discontinuation of imatinib. Cancer Sci (2013) 0.93
Sulfatide is required for efficient replication of influenza A virus. J Virol (2008) 0.93
Integration of human T-cell leukemia virus type 1 in genes of leukemia cells of patients with adult T-cell leukemia. Cancer Sci (2004) 0.92
Role for Btg1 and Btg2 in growth arrest of WEHI-231 cells through arginine methylation following membrane immunoglobulin engagement. Exp Cell Res (2007) 0.92
Effects of IL-23 and IL-27 on osteoblasts and osteoclasts: inhibitory effects on osteoclast differentiation. J Bone Miner Metab (2007) 0.91
Positive modulation of IL-12 signaling by sphingosine kinase 2 associating with the IL-12 receptor beta 1 cytoplasmic region. J Immunol (2003) 0.91
Antimelanoma immunotherapy: clinical and preclinical applications of IL-12 family members. Immunotherapy (2010) 0.90
IL-27 enhances the expression of TRAIL and TLR3 in human melanomas and inhibits their tumor growth in cooperation with a TLR3 agonist poly(I:C) partly in a TRAIL-dependent manner. PLoS One (2013) 0.89
Requirement of c-Jun NH2-terminal kinase activation in interferon-alpha-induced apoptosis through upregulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in Daudi B lymphoma cells. Exp Cell Res (2005) 0.89
Expression of interleukins-23 and 27 leads to successful gene therapy of hepatocellular carcinoma. Mol Immunol (2009) 0.87
Tumor necrosis factor-related apoptosis-inducing ligand induces apoptotic cell death through c-Jun NH2-terminal kinase activation in squamous cell carcinoma cells. Oncol Rep (2009) 0.87
Synergistic antitumor effect by coexpression of chemokine CCL21/SLC and costimulatory molecule LIGHT. Cancer Gene Ther (2004) 0.86
Massive liver necrosis after provocation of imbalance between Th1 and Th2 immune reactions in osteopontin transgenic mice. J Gastroenterol (2004) 0.86
Design, synthesis, and evaluation of isoindolinone-hydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors. Bioorg Med Chem Lett (2007) 0.85
IL-27 suppresses RANKL expression in CD4+ T cells in part through STAT3. Immunol Lett (2011) 0.85
Interferon-alpha induces transient upregulation of c-FLIP through NF-kappaB activation. Exp Cell Res (2007) 0.85
Interferon-alpha-induced apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-dependent and -independent manner. Oncol Rep (2007) 0.85
Blockade of the OX40 ligand prolongs corneal allograft survival. Eur J Immunol (2007) 0.84
Antitumor activities of interleukin-27 on melanoma. Endocr Metab Immune Disord Drug Targets (2010) 0.84
Interleukins and cancer immunotherapy. Immunotherapy (2009) 0.83
Immunogenic variation between multiple HLA-A*0201-restricted, Hepatitis C Virus-derived epitopes for cytotoxic T lymphocytes. Viral Immunol (2006) 0.83
Roles of CXC chemokines and macrophages in the recruitment of inflammatory cells and tumor rejection induced by Fas/Apo-1 (CD95) ligand-expressing tumor. Int J Cancer (2005) 0.83
Chemotherapeutic agents sensitize sarcoma cell lines to tumor necrosis factor-related apoptosis-inducing ligand-induced caspase-8 activation, apoptosis and loss of mitochondrial membrane potential. J Orthop Res (2003) 0.83
Transgenic mice expressing osteopontin in hepatocytes as a model of autoimmune hepatitis. Biochem Biophys Res Commun (2004) 0.82
Apoptosis induced by chemotherapeutic agents involves c-Jun N-terminal kinase activation in sarcoma cell lines. J Orthop Res (2006) 0.82
Zebrafish and mouse alpha2,3-sialyltransferases responsible for synthesizing GM4 ganglioside. J Biol Chem (2009) 0.82
PKC-δ mediates interferon-α-induced apoptosis through c-Jun NH₂-terminal kinase activation. BMC Cell Biol (2012) 0.81
Interferon-beta-induced activation of c-Jun NH2-terminal kinase mediates apoptosis through up-regulation of CD95 in CH31 B lymphoma cells. Exp Cell Res (2004) 0.81
Interleukin (IL)-17 versus IL-27: opposite effects on tumor necrosis factor-α-mediated chemokine production in human keratinocytes. Exp Dermatol (2011) 0.81
C-jun N-terminal kinase activation is required for apoptotic cell death induced by TNF-related apoptosis-inducing ligand plus DNA-damaging agents in sarcoma cell lines. Anticancer Res (2006) 0.81